Study of a new injection for teens with moderate-to-severe eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new medicine, MG-K10, given as an injection, to see if it can reduce eczema symptoms like itching and skin rash in teenagers. It's for teens whose eczema is not well controlled with topical treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had atopic dermatitis (eczema) for at least 6 months
- Your eczema covers at least 10% of your body and is moderate to severe
- Prescription creams or ointments haven't worked well enough
- You can receive injections (no severe needle fear or bleeding problems)
- You have not taken certain eczema medicines, like biologics, JAK inhibitors, or immunosuppressants, within the past few weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injectable medicine (611) for teenagers with moderate to severe eczema that hasn't been helped enough by creams. It aims to see if the drug can safely reduce itching and skin symptoms.
This study tests a new medicine (called 611) given as an injection to children with moderate-to-severe eczema that hasn't improved with creams. The goal is to see if it can reduce itching and clear the rash.
This trial tests an injectable medicine called SHR-1819 for teenagers aged 12 to 17 with severe atopic dermatitis (eczema) that has not responded well to creams or other treatments. The goal is to see if it can improve skin symptoms and reduce itching.
This study tests a new injectable medication called MG-K10 for teens with moderate to severe eczema that hasn't been well controlled with creams. The goal is to see if it can safely reduce inflammation and improve skin symptoms.
This study tests a new injectable medication called MG-K10 for people with moderate to severe atopic dermatitis (eczema). The goal is to see if it reduces itching and clears skin better than a placebo. If you've tried topical treatments without enough relief, this might be an option.
This trial tests an investigational drug called BxC-I17e, given as an injection under the skin, for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with standard creams. The goal is to see if it is safe and works well.
Hear when a new Dermatitis, Atopic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.